Latest Earnings Results: Q2 '26
Estimated EPS
$0.11
Reported EPS
$0.14
Surprise
+27.27%
Estimated Rev
$33.88M
Reported Rev
$39.66M
Surprise
+17.06%
• Reported GAAP EPS of $0.14 down -88.71% YoY • Reported revenue of $39.66M up 53.25% YoY
Bullish Takeaway
Zevra Therapeutics delivered strong revenue growth and expanded its intellectual property protection for MIPLYFFA, while continuing to advance the clinical development of its pipeline candidate celiprolol for Vascular Ehlers-Danlos Syndrome.
Bearish Takeaway
Zevra Therapeutics experienced a significant year-over-year decline in net income, while safety risks including hypersensitivity reactions and uncertainties regarding the clinical significance of therapeutic mechanisms remain key business challenges.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.14 | -- | -- | N/A |
Q2 '26 | $0.11 | $0.14 | 27.27% | BEAT |
Q1 '26 | $0.08 | $0.60 | 639.73% | BEAT |
Q4 '25 | $0.05 | $0.19 | 276.98% | BEAT |
Q3 '25 | -$0.03 | -$0.01 | 70.37% | BEAT |